Zevra Therapeutics (NASDAQ:ZVRA) Sets New 1-Year High – Here’s What Happened

Zevra Therapeutics, Inc. (NASDAQ:ZVRA) shares hit a new 52-week high during trading on Wednesday . The company traded as high as $14.75 and last traded at $14.7450, with a volume of 102392 shares. The stock had previously closed at $14.44.

Wall Street Analyst Weigh In

Several research analysts recently weighed in on the company. Citigroup reiterated an “outperform” rating on shares of Zevra Therapeutics in a research report on Tuesday, June 9th. UBS Group restated a “buy” rating on shares of Zevra Therapeutics in a research report on Wednesday, June 24th. Canaccord Genuity Group raised their price objective on shares of Zevra Therapeutics from $24.00 to $29.00 and gave the stock a “buy” rating in a research note on Tuesday, June 9th. Cantor Fitzgerald boosted their target price on shares of Zevra Therapeutics from $24.00 to $34.00 and gave the company an “overweight” rating in a research note on Monday, June 8th. Finally, Guggenheim increased their price target on shares of Zevra Therapeutics from $25.00 to $29.00 and gave the stock a “buy” rating in a report on Wednesday, June 10th. Nine research analysts have rated the stock with a Buy rating and two have given a Hold rating to the company’s stock. According to data from MarketBeat.com, the company has an average rating of “Moderate Buy” and a consensus price target of $29.29.

Zevra Therapeutics Stock Down 1.0%

The firm has a market capitalization of $845.36 million, a PE ratio of 7.20 and a beta of 0.85. The stock has a 50-day moving average price of $11.85 and a 200 day moving average price of $10.10.

Zevra Therapeutics (NASDAQ:ZVRA) last posted its quarterly earnings data on Wednesday, May 6th. The company reported $0.18 earnings per share for the quarter, topping analysts’ consensus estimates of $0.06 by $0.12. The company had revenue of $36.22 million during the quarter, compared to analysts’ expectations of $31.96 million. Zevra Therapeutics had a net margin of 101.58% and a return on equity of 51.49%. As a group, equities analysts predict that Zevra Therapeutics, Inc. will post 0.56 earnings per share for the current fiscal year.

Institutional Investors Weigh In On Zevra Therapeutics

Several institutional investors have recently bought and sold shares of ZVRA. Gunpowder Capital Management LLC dba Oliver Wealth Management acquired a new position in shares of Zevra Therapeutics during the fourth quarter valued at approximately $53,000. Russell Investments Group Ltd. raised its stake in Zevra Therapeutics by 235.7% in the 3rd quarter. Russell Investments Group Ltd. now owns 6,374 shares of the company’s stock valued at $61,000 after purchasing an additional 4,475 shares during the last quarter. Tower Research Capital LLC TRC raised its stake in Zevra Therapeutics by 617.5% in the 2nd quarter. Tower Research Capital LLC TRC now owns 9,937 shares of the company’s stock valued at $88,000 after purchasing an additional 8,552 shares during the last quarter. Creative Planning purchased a new position in Zevra Therapeutics in the 2nd quarter valued at $92,000. Finally, Quarry LP purchased a new position in Zevra Therapeutics in the 3rd quarter valued at $103,000. 35.03% of the stock is currently owned by institutional investors and hedge funds.

Zevra Therapeutics Company Profile

Zevra Therapeutics, Inc discovers and develops various proprietary prodrugs to treat serious medical conditions in the United States. The company develops its products through Ligand Activated Therapy platform. Its lead product candidate is KP1077, consisting of KP1077IH, which is under Phase 2 clinical trial for the treatment of idiopathic hypersomnia, and KP1077N, which is under Phase ½ clinical trial to treat narcolepsy. The company is also developing Celiprolol, a prodrug product candidate that is under Phase 1/2 clinical trial for the treatment of vascular Ehlers Danlos syndrome.